Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials

Cristina Tarango, Sam Schulman, Marisol Betensky, Neil Goldenberg

Research output: Contribution to journalReview article

Abstract

Introduction: Compared with the incidence of venous thromboembolism in the adult population, pediatric VTE is rare. Yet, recent data suggest that the incidence of VTE in children is increasing, and little is known about the optimal duration of anticoagulation in pediatrics. Areas covered: This review summarizes current evidence-based adult recommendations and associated clinical trials from which current guidelines on the duration of anticoagulation in children have been extrapolated. It also discusses pediatric expert consensus-based guidelines and current pediatric clinical trials on duration of therapy in pediatric VTE. Expert commentary: The vast majority of pediatric VTE are provoked, and evidence on duration of anticoagulation for pediatric VTE is highly limited, but suggests that a maximum duration of 3 months is reasonable for most patients with provoked VTE, whereas longer duration is likely appropriate for unprovoked VTE. Whether shorter duration than 3 months is optimal for pediatric provoked VTE is as yet unclear. Results from the multinational randomized controlled trial studying the duration of anticoagulant therapy for provoked VTE in patients <21 years old (Kids-DOTT) will be critical to inform the future standard of care in pediatric VTE treatment.

Original languageEnglish (US)
Pages (from-to)37-44
Number of pages8
JournalExpert Review of Hematology
Volume11
Issue number1
DOIs
StatePublished - Jan 2 2018

Fingerprint

Venous Thromboembolism
Anticoagulants
Randomized Controlled Trials
Pediatrics
Therapeutics
Clinical Trials
Guidelines
Incidence
Standard of Care

Keywords

  • Duration of anticoagulation
  • guidelines
  • pediatrics
  • randomized trial
  • venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Duration of anticoagulant therapy in pediatric venous thromboembolism : Current approaches and updates from randomized controlled trials. / Tarango, Cristina; Schulman, Sam; Betensky, Marisol; Goldenberg, Neil.

In: Expert Review of Hematology, Vol. 11, No. 1, 02.01.2018, p. 37-44.

Research output: Contribution to journalReview article

@article{28f561e9f07a4a218801c23fc1c6130e,
title = "Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials",
abstract = "Introduction: Compared with the incidence of venous thromboembolism in the adult population, pediatric VTE is rare. Yet, recent data suggest that the incidence of VTE in children is increasing, and little is known about the optimal duration of anticoagulation in pediatrics. Areas covered: This review summarizes current evidence-based adult recommendations and associated clinical trials from which current guidelines on the duration of anticoagulation in children have been extrapolated. It also discusses pediatric expert consensus-based guidelines and current pediatric clinical trials on duration of therapy in pediatric VTE. Expert commentary: The vast majority of pediatric VTE are provoked, and evidence on duration of anticoagulation for pediatric VTE is highly limited, but suggests that a maximum duration of 3 months is reasonable for most patients with provoked VTE, whereas longer duration is likely appropriate for unprovoked VTE. Whether shorter duration than 3 months is optimal for pediatric provoked VTE is as yet unclear. Results from the multinational randomized controlled trial studying the duration of anticoagulant therapy for provoked VTE in patients <21 years old (Kids-DOTT) will be critical to inform the future standard of care in pediatric VTE treatment.",
keywords = "Duration of anticoagulation, guidelines, pediatrics, randomized trial, venous thromboembolism",
author = "Cristina Tarango and Sam Schulman and Marisol Betensky and Neil Goldenberg",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/17474086.2018.1407241",
language = "English (US)",
volume = "11",
pages = "37--44",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Duration of anticoagulant therapy in pediatric venous thromboembolism

T2 - Current approaches and updates from randomized controlled trials

AU - Tarango, Cristina

AU - Schulman, Sam

AU - Betensky, Marisol

AU - Goldenberg, Neil

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Introduction: Compared with the incidence of venous thromboembolism in the adult population, pediatric VTE is rare. Yet, recent data suggest that the incidence of VTE in children is increasing, and little is known about the optimal duration of anticoagulation in pediatrics. Areas covered: This review summarizes current evidence-based adult recommendations and associated clinical trials from which current guidelines on the duration of anticoagulation in children have been extrapolated. It also discusses pediatric expert consensus-based guidelines and current pediatric clinical trials on duration of therapy in pediatric VTE. Expert commentary: The vast majority of pediatric VTE are provoked, and evidence on duration of anticoagulation for pediatric VTE is highly limited, but suggests that a maximum duration of 3 months is reasonable for most patients with provoked VTE, whereas longer duration is likely appropriate for unprovoked VTE. Whether shorter duration than 3 months is optimal for pediatric provoked VTE is as yet unclear. Results from the multinational randomized controlled trial studying the duration of anticoagulant therapy for provoked VTE in patients <21 years old (Kids-DOTT) will be critical to inform the future standard of care in pediatric VTE treatment.

AB - Introduction: Compared with the incidence of venous thromboembolism in the adult population, pediatric VTE is rare. Yet, recent data suggest that the incidence of VTE in children is increasing, and little is known about the optimal duration of anticoagulation in pediatrics. Areas covered: This review summarizes current evidence-based adult recommendations and associated clinical trials from which current guidelines on the duration of anticoagulation in children have been extrapolated. It also discusses pediatric expert consensus-based guidelines and current pediatric clinical trials on duration of therapy in pediatric VTE. Expert commentary: The vast majority of pediatric VTE are provoked, and evidence on duration of anticoagulation for pediatric VTE is highly limited, but suggests that a maximum duration of 3 months is reasonable for most patients with provoked VTE, whereas longer duration is likely appropriate for unprovoked VTE. Whether shorter duration than 3 months is optimal for pediatric provoked VTE is as yet unclear. Results from the multinational randomized controlled trial studying the duration of anticoagulant therapy for provoked VTE in patients <21 years old (Kids-DOTT) will be critical to inform the future standard of care in pediatric VTE treatment.

KW - Duration of anticoagulation

KW - guidelines

KW - pediatrics

KW - randomized trial

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85039157147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039157147&partnerID=8YFLogxK

U2 - 10.1080/17474086.2018.1407241

DO - 10.1080/17474086.2018.1407241

M3 - Review article

C2 - 29183221

AN - SCOPUS:85039157147

VL - 11

SP - 37

EP - 44

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 1

ER -